Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.

Authors

Senthil Damodaran

The University of Texas MD Anderson Cancer Center, Houston, TX

Senthil Damodaran , Paul V. Plourde , Halle C. F. Moore , Ian Churchill Anderson , David Jay Portman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update.

First Author: Senthil Damodaran

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC).

First Author: Mafalda Oliveira

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Initial results from a phase II study.

First Author: Tamta Makharadze

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

First Author: Sara M. Tolaney